ArticleInvestigative ophthalmology & visual science2026
Risk of Glaucoma Progression in Patients Using a Calcium Channel Blocker: A Propensity-Matched Cohort Study.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the potential impact of calcium channel blocker (CCB) use on the progression of mild to moderate POAG to the severe stage. Methods: A retrospective cohort analysis was conducted using the TriNetX United States Collaborative Network to identify patients with mild or moderate POAG and more than 6 months of follow-up data. Patients were stratified by CCB use. The primary outcome was disease progression to severe POAG at any time point after the initial diagnosis, identified using International Classification of Diseases, Tenth Revision, code H40.1193. Patients with prior severe POAG or those prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers were excluded. Propensity score matching (1:1) was conducted to control for age, sex, race, ethnicity, and hypertension. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Results: After propensity score matching, 7446 patients were included: 3723 controls (no CCB use), 3039 taking dihydropyridine CCBs (dCCBs), and 684 taking nondihydropyridine CCBs (ndCCBs). The risk of severe POAG was significantly higher in patients using dCCBs (RR, 1.67; 95% CI, 1.23-2.27) and ndCCBs (RR, 3.62; 95% CI, 1.97-6.62) compared with controls. Conclusions: Both dCCBs and ndCCBs were associated with an increased risk of progression to severe POAG in patients with mild to moderate disease. Further research is needed to elucidate the underlying mechanisms of this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.